Raven Provides OMNiPOWER™ Platform for World’s First OMNi Farm Enterprise
15.6.2021 16:15:00 EEST | Business Wire | Press release
Raven Industries, Inc. (the Company; NASDAQ:RAVN), the leader in autonomous agriculture technology, announced today the purchase of a second OMNiPOWER™ platform by Haggerty AgRobotics. Raven’s driverless ag and precision technology deliver impactful solutions for local and enterprise farms as the agriculture industry’s labor shortages continue to grow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005181/en/
The second OMNiPOWER platform will allow Haggerty AgRobotics to lead the industry as one of the first customers to implement a real-world fleet of autonomous machines. Haggerty AgRobotics will now manage a fleet of OMNi platforms with machine-to-machine connectivity through the Viper® 4+ field computer. (Photo: Business Wire)
“Labor shortage concerns within our local growers have really elevated the need for more automation and robotics on the farm,” said Chuck Baresich, President of Haggerty AgRobotics.
Haggerty Creek Ltd., an establised company delivering grain and crop input needs for growers in Ontario, Canada, has been collaborating with Raven to solve industry challenges for over a decade. In 2020, Haggerty Creek Ltd. purchased its first OMNiPOWER and in 2021 purchased OMNiDRIVE to help farmers with operational challenges they face. The growing demand for driverless ag technology as an impactful solution for labor shortages pushed Baresich to launch Haggerty AgRobotics, a service focused entirely on autonomy, robotics and technology automation at the farm level.
The second OMNiPOWER platform will allow Haggerty AgRobotics to lead the industry as one of the first customers to implement a real-world fleet of autonomous machines. Baresich will now manage a fleet of OMNi platforms with machine-to-machine connectivity through the Viper® 4+ field computer. The integration of Raven’s advanced precision farming technology within the OMNiPOWER platform allows for a seamless user experience and real-time shared coverage visibility.
“As one of the first customers of this technology, we are very excited to bring Raven driverless ag solutions to the market in a big way,” said Baresich. “The recent updates and advancements to Raven’s technology are impressive and we have experienced incredible performance in our 2021 spring program. We purchased our second OMNiPOWER platform to continue to be on the leading edge of commercializing autonomous machines as an organized fleet.”
“Raven has made significant investments in our OMNi suite of driverless ag solutions,” said Ben Voss, Raven Applied Technology Director of Sales for North America and Australia. “It is exciting to see a progressive, ag-tech focused operation like Haggerty AgRobotics partner with us to showcase autonomy and precision applications in the agriculture market. OMNiPOWER and OMNiDRIVE position both of us as autonomy pioneers in the global agriculture industry.”
Raven unveiled their OMNi brand of autonomous solutions less than a month ago and is actively fulfilling orders for both OMNiPOWER and OMNiDRIVE™ units worldwide. OMNiPOWER™ is a self-propelled power platform that easily interchanges farm implements like a sprayer or spreader. This autonomous platform empowers ag professionals to perform multiple farm tasks simultaneously without a driver. Raven’s Path to Autonomy begins with precision farming products that reduce driver fatigue and graduates up to full driverless ag technology automation.
By investing in driverless ag technology, Raven continues to design solutions that reduce operating costs, decrease inputs, and improve yields for ag professionals around the world. Available to order today at RavenPrecision.com.
About Raven Industries, Inc.
Raven Industries (NASDAQ: RAVN) is dedicated to providing innovative, high-value products and solutions that solve great challenges throughout the world. Raven is a leader in precision agriculture, high-performance specialty films, and lighter-than-air technologies. Since 1956, Raven has designed, produced, and delivered exceptional solutions, earning the company a reputation for innovation, product quality, high performance, and unmatched service. For more information, visit https://ravenind.com.
About Raven Applied Technology
For decades, Raven Applied Technology has been committed to maximizing operational efficiencies through its innovative agriculture technology. The company’s autonomous product suite, Raven Autonomy™, is an extension of that core. From field computers to sprayer and planter controls, GPS guidance steering systems, logistics technology, and autonomous solutions — Raven provides precision agriculture products designed for ag retailers and growers to remain competitive and profitable into the future. Learn more at https://ravenprecision.com.
About Haggerty Creek Ltd.
Haggerty Creek Ltd. was established in 2001 to fill a market need in Ontario’s four counties area, being Lambdon, Middlesex, Elgin and Kent counties. Located north of Bothwell, Ontario, Haggerty Creek provides whole farm solutions, starting with precision crop planning and application, and ending with grain handling and marketing. In response to the growing demand for driverless ag technology, the company launched Haggerty AgRobotics, positioning themselves as a pioneer in a growing industry. Learn more at https://haggertycreek.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005181/en/
Contact information
Erin Rinehart, Marketing Manager
Raven Industries
+1 (605) 336-2750
erin.rinehart@ravenind.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom